Early Outcomes of Flebogrif®, a Mechanochemical Ablation Technique, for Treating Chronic Venous Disorders
Year: 2024
Type: article
Abstract: Chronic venous diorder Mechanochemical ablation FlebogrifObjective Flebogrif ® is a new mechanochemical ablation (MOCA) technique for treating chronic venous disorders (CVD), with limited studies available.This study provides early clinical outcomes from its use in South Korea.Methods A retrospective analysis was conducted on 55 patients treated with Flebogrif ® at a Charm Vascular Clinic in Seoul.Mechanical injury combined with foam sclerosant (2% STS and CO 2 ) was applied to 113 saphenous veins.Primary outcomes were anatomical success at 1 and 3 months, with secondary outcomes included adverse events, pain scores, rVCSS score, CIVIQ14 score, time to return to normal activities and foam sclerosant dosages. ResultsThe anatomical success rate were analyzed as 97.3% at 1 month and 96.9% at 3 months.Adverse events were mild, with no occurrences of severe events such as paresthesia or deep vein thrombosis (DVT).The mean time returned to normal activities was 1.07±0.42days.Notably, Flebogrif ® allowed treatment of multiple veins without increased risk, averaging a foam sclerosant volume of 15.85±5.71cc per procedure.rVCSS and CIVIQ14 scores showed a statistically significant decrease from the initial scores.Conclusion Flebogrif ® shows promise as an effective and safe treatment for CVD, achieving comparable results to other methods with potential cost benefits.Further studies are recommended for validation.
Source: Annals of Phlebology
Authors: Insoo Park, Sujin Park
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W4406112981